arrow_back Back Filing freshness 10-Q Q2 FY2027 SEC EDGAR

LIFECORE BIOMEDICAL, INC. \DE\

LFCR
$6.39 ▼ -0.04 (-0.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

LIFECORE BIOMEDICAL, INC. \DE\ faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $240.1M
Dividend Yield —
Revenue Growth None
Op. Margin 7.5%
ROIC None
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.17M
↑ +9.8% —
Net Income Profit after all expenses
$-6.16M
↑ +38.4% —
Operating Margin Operating profit as % of sales
7.5%
↑ +176.2% 13th
FCF / Share Free cash flow per share
$0.00
↑ +100.2% —
Long-Term Debt Long-term obligations
$155.07M
↑ +4.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
11
Financial Health →
23
Cash Quality ↑
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 67 quarters